Fig. 10From: Management of retinitis pigmentosa by Wharton’s jelly-derived mesenchymal stem cells: prospective analysis of 1-year results“Visual field” enlargement according to study timepoints (T0, T1, T2) in the eye treated with WJ-MSCs. Note the change in FPDI (Table 1, patient 6: left eye). a Before application, FPDI 7%. b At 6th month, FPDI 13%. c At 12th month, FPDI 14%Back to article page